SHANGHAI, Feb. 26, 2018 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner MabSpace Biosciences for FDA Investigational New Drug (IND) clearance for MSB2311, a second generation PD-L1 antibody with a pH-dependent antigen binding and recycling property.

MabSpace Biosciences announced on February 16, 2018 FDA cleared IND for MSB2311, a humanized PD-L1 antibody for the treatment of patients with locally advanced/metastatic solid tumors. As part of the collaboration, WuXi Biologics provided comprehensive and integrated services for MSB2311 from cell line development, process, analytical and formulation development, to GMP manufacturing.

"We are pleased to work with WuXi Biologics on our immuno-oncology programs. The clearance of MSB2311 IND by FDA marks an important milestone for MabSpace," said Xueming Qian, Ph.D, Founder, Chairman and CEO of MabSpace. "WuXi Biologics' state-of-the-art and full-service biologics platform enabled us to complete a solid CMC package in support of our IND submission and clearance. We are excited about this molecule in potentially providing a differentiated and more efficacious immuno-therapeutic agent for cancer patients around the world."

"Congratulations to MabSpace on achieving this great company milestone of MSB2311 IND," said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. "We are honored to enable innovative partners like MabSpace through WuXi Biologics' integrated and open-access biologics technology platform, and we wish the program great clinical success to benefit patients worldwide."

About MabSpace Biosciences
MabSpace Biosciences Co., Ltd. specializes in the discovery, development and commercialization of antibody-based therapeutics, with a focus on developing best-in-class and first-in-class antibody therapeutics for cancer treatment. MabSpace is headquartered in Suzhou, with a fully-integrated antibody discovery and development facility in Biobay, Suzhou Industrial Park, China. For more information on MabSpace, please visit www.mabspacebio.com. 

SOURCE WuXi Biologics